Enhancing the accessibility of psychedelic healthcare
To strengthen the adoption of psychedelic-assisted therapies, drug developers are striving to minimise their cost – with shorter lasting tryptamines.
Psilocybin can induce altered states of consciousness for over ten hours, during which time patients need to be supervised by trained practitioners. DMT and 5-MeO-DMT have much shorter onset and offset times, enabling treatments in under 90 minutes.
UK-based Small Pharma and Beckley Psytech are conducting clinical trials with DMT and 5-MeO-DMT to treat major depressive disorder and treatment-resistant depression.
PSYCH spoke with Beckley Psytech’s Chief Scientific Officer, Stephen Wooding, and Small Pharma’s Chief Medical and Scientific Officer, Carol Routledge, on streamlining psychedelic-assisted therapy.Read More